Cosciens Biopharma Inc.
COSCIENS Biopharma Inc. is a Toronto-based life science company focused on developing and commercializing natural, plant-based active ingredients and pharmaceutical and diagnostic products. Its active ingredient business centers on oat-derived ingredients such as oat beta glucan and avenanthramides, which are used in personal care, cosmetic, and health-related applications. The company also works in pharmaceuticals through its lead oral diagnostic test for adult growth hormone deficiency, alongside other product development activities in biopharmaceutical markets. COSCIENS Biopharma Inc. operates through active ingredient and pharmaceutical segments, serving customers and partners in the healthcare, cosmetics, nutraceutical, and specialty life sciences industries. The company’s portfolio reflects a blend of ingredient innovation and clinical product commercialization within the broader biopharmaceutical sector.
$6.49
+$0.24 (+3.84%)
EOD Oct 16, 2026
The business is unprofitable at the operating level (-138.24% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Negative free cash flow of -$9M. The business is consuming cash, not generating it.
1.4x earnings. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$8M
Net Income (TTM)
$7M
Op. Margin
-56.80%
ROIC
-136.68%
Cash Flow & Balance Sheet
FCF (TTM)
-$4M
Op. Cash Flow (TTM)
-$4M
Net Debt
-$5M
Net Cash Position
Cash & Equiv.
$7M
Continue Research
Is Cosciens Biopharma (CSCIF) overvalued?
At a P/E of 1.4, Cosciens Biopharma (CSCIF)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Cosciens Biopharma scores 20/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from company filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is Cosciens Biopharma a high-quality business?+
Cosciens Biopharma scores 20 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -56.8% operating margin and a -136.7% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from company filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is Cosciens Biopharma a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh CSCIF's valuation and scores 20/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from company filings, not investment advice.
Related stocks: Biotechnology
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.